Pandemic research

2020 has been marked by the SARS-CoV-2 pandemic, which has wreaked havoc worldwide and has demonstrated, once and for all, the importance of research.

The virology and immune system expertise accumulated in IrsiCaixa over 25 years has enabled it to rapidly launch SARS-CoV-2 research projects and brought it to the forefront of the fight against the virus. Its projects focus on different aspects of the coronavirus, including prevention, detection and treatment.

The response has been deliberately rapid and collaborative in order to be able to deliver results in the shortest possible time. IrsiCaixa is currently cooperating with other institutions to develop a coronavirus vaccine and drugs and is participating in a clinical trial to reduce transmissions.

We share in open access and real time the results of in vitro experiments to combat SARS-CoV-2 using existing drugs, in order to provide rapid and updated information for the design of clinical trials. We have also designed and shared a SARS-CoV-2 antibody detection ELISA test that can be done without commercial kits and have generated a list of molecules of the virus that will allow laboratories to work towards the same direction in the study of long-term immunity against the new coronavirus.

This page brings together all information regarding our coronavirus research.